drugset
drugset / Trial / NCT04200365

A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

NCT04200365 ↗

Phase 2 Terminated 15 enrolled SCRI Development Innovations, LLC Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months. The purpose of this study is to find out if itacitinib in combination with corticosteroids or other immunosuppressive therapies is safe and effective in people with cGVHD.

Timeline

Start
2020-06-05
Primary completion
2023-09-07
Completion
2023-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Itacitinib Small molecule — Oral

Indications

chronic graft versus host disease